Tackling Mental Health through New Targets and Endpoints Progress
February 11, 2025
Astor
The October 2024 approval of the first schizophrenia drug with a new mechanism of action since the 1950s heralds an acceleration of investment interest in supporting new medicines for neuropsychiatric diseases. Companies pursuing new targets and working with patients or defining the most critical endpoints will explain opportunities for this still underserved space.
Speakers
.jpg)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}